Abeona Therapeutics has appointed Dr Carsten Thiel as CEO. Carsten brings 25 years of proven global biopharmaceutical industry experience, including rare and orphan diseases, to Abeona. Prior to leading his most recent position at Alexion, he served as its senior VP, Europe/Middle East/Africa and Asia Pacific where he was responsible for driving Alexion’s global commercial operations in these regions, including maximising the current rare disease portfolio as well as guiding the launch of anticipated new products and indications.
